Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olpasiran PK/PD in Chinese Subjects with Elevated Lp(a)
NCT04987320Phase 1Completed
- Sponsor
- Amgen
- Start
- Jul 2021
- Primary completion
- Nov 2021
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olpasiran in elevated lipoprotein(a) (Lp(a)) (2 arms), sponsored by Amgen. Primary endpoint: Maximum Observed Concentration at Day 85. Started Jul 2021; status: completed.
02
Drugs
olpasiran
03
Conditions
elevated lipoprotein(a) (Lp(a))
Beyond the preview
Go deeper on NCT04987320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04987320.